Your browser doesn't support javascript.
loading
TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC.
Tammaccaro, Salvina Laura; Prigent, Philippe; Le Bail, Jean-Christophe; Dos-Santos, Odette; Dassencourt, Laurent; Eskandar, Myriam; Buzy, Armelle; Venier, Olivier; Guillemot, Jean-Claude; Veeranagouda, Yaligara; Didier, Michel; Spanakis, Emmanuel; Kanno, Tokuwa; Cesaroni, Matteo; Mathieu, Stephane; Canard, Luc; Casse, Alhassan; Windenberger, Fanny; Calvet, Loreley; Noblet, Laurence; Sidhu, Sukhvinder; Debussche, Laurent; Moll, Jurgen; Valtingojer, Iris.
Afiliação
  • Tammaccaro SL; Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Prigent P; Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Le Bail JC; Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Dos-Santos O; Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Dassencourt L; Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Eskandar M; Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Buzy A; Bio Structure and Biophysics, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Venier O; Small Molecules Medicinal Chemistry, Sanofi R&D, 91380 Chilly-Mazarin, France.
  • Guillemot JC; Genomics and Proteomics, Translational Sciences, Sanofi R&D, 91380 Chilly-Mazarin, France.
  • Veeranagouda Y; Genomics and Proteomics, Translational Sciences, Sanofi R&D, 91380 Chilly-Mazarin, France.
  • Didier M; Genomics and Proteomics, Translational Sciences, Sanofi R&D, 91380 Chilly-Mazarin, France.
  • Spanakis E; Precision Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Kanno T; Precision Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Cesaroni M; Precision Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Mathieu S; Molecular & Digital Histopathology, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Canard L; Molecular & Digital Histopathology, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Casse A; Molecular & Digital Histopathology, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Windenberger F; Non-Clinical Efficacy and Safety, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Calvet L; Pharmacology, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Noblet L; Pharmacology, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Sidhu S; Pharmacology, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Debussche L; Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Moll J; Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Valtingojer I; Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France.
Pharmaceuticals (Basel) ; 16(4)2023 Apr 06.
Article em En | MEDLINE | ID: mdl-37111311
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França